CorynoxeineCAS# 630-94-4 |
- Isocorynoxeine
Catalog No.:BCN5003
CAS No.:51014-29-0
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 630-94-4 | SDF | Download SDF |
| PubChem ID | 44568160 | Appearance | Powder |
| Formula | C22H26N2O4 | M.Wt | 382.45 |
| Type of Compound | Alkaloids | Storage | Desiccate at -20°C |
| Solubility | Methanol : 125 mg/mL (326.84 mM; Need ultrasonic) DMSO : ≥ 3.8 mg/mL (9.94 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | methyl (E)-2-[(3R,6'R,7'S,8'aS)-6'-ethenyl-2-oxospiro[1H-indole-3,1'-3,5,6,7,8,8a-hexahydro-2H-indolizine]-7'-yl]-3-methoxyprop-2-enoate | ||
| SMILES | COC=C(C1CC2C3(CCN2CC1C=C)C4=CC=CC=C4NC3=O)C(=O)OC | ||
| Standard InChIKey | MUVGVMUWMAGNSY-KAXDATADSA-N | ||
| Standard InChI | InChI=1S/C22H26N2O4/c1-4-14-12-24-10-9-22(17-7-5-6-8-18(17)23-21(22)26)19(24)11-15(14)16(13-27-2)20(25)28-3/h4-8,13-15,19H,1,9-12H2,2-3H3,(H,23,26)/b16-13+/t14-,15-,19-,22+/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Corynoxeine is a potent ERK1/2 inhibitor of key PDGF-BB-induced VSMC proliferation and may be useful in the prevention and treatment of vascular diseases and restenosis after angioplasty. |
| Targets | ERK | MEK | Akt | DNA/RNA Synthesis | MAPK |
| In vitro | Isolation and identification of twelve metabolites of isocorynoxeine in rat urine and their neuroprotective activities in HT22 cell assay.[Pubmed: 25519834]Planta Med. 2015 Jan;81(1):46-55.IsoCorynoxeine, one of the major alkaloids from Uncaria Hook, shows the effects of lowering blood pressure, vasodilatation, and protection against ischemia-induced neuronal damage. In this paper, the metabolism of isoCorynoxeine was investigated in rats. Twelve metabolites and the parent drug were isolated by using solvent extraction and repeated chromatographic methods, and determined by spectroscopic methods including UV, MS, NMR, and CD experiments. |
| Kinase Assay | Corynoxeine isolated from the hook of Uncaria rhynchophylla inhibits rat aortic vascular smooth muscle cell proliferation through the blocking of extracellular signal regulated kinase 1/2 phosphorylation.[Pubmed: 18981576]Biol Pharm Bull. 2008 Nov;31(11):2073-8.The proliferation of vascular smooth muscle cells (VSMCs) induced by injury to the intima of arteries is an important etiologic factor in vascular proliferative disorders such as atherosclerosis and restenosis. Uncaria rhynchophylla is traditional Chinese herb that has been applied to the treatment of convulsive disorders, such as epilepsy, in China. |
Corynoxeine Dilution Calculator
Corynoxeine Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.6147 mL | 13.0736 mL | 26.1472 mL | 52.2944 mL | 65.368 mL |
| 5 mM | 0.5229 mL | 2.6147 mL | 5.2294 mL | 10.4589 mL | 13.0736 mL |
| 10 mM | 0.2615 mL | 1.3074 mL | 2.6147 mL | 5.2294 mL | 6.5368 mL |
| 50 mM | 0.0523 mL | 0.2615 mL | 0.5229 mL | 1.0459 mL | 1.3074 mL |
| 100 mM | 0.0261 mL | 0.1307 mL | 0.2615 mL | 0.5229 mL | 0.6537 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Phenytoin sodium
Catalog No.:BCC5071
CAS No.:630-93-3
- Ouabain
Catalog No.:BCC5069
CAS No.:630-60-4
- Nonacosane
Catalog No.:BCC9102
CAS No.:630-03-5
- Phenoxybenzamine HCl
Catalog No.:BCC4334
CAS No.:63-92-3
- L-Phenylalanine
Catalog No.:BCN3818
CAS No.:63-91-2
- Sulfanilamide
Catalog No.:BCC4858
CAS No.:63-74-1
- H-Met-OH
Catalog No.:BCC2993
CAS No.:63-68-3
- Primaquine Diphosphate
Catalog No.:BCC4706
CAS No.:63-45-6
- Androstenedione
Catalog No.:BCC8296
CAS No.:63-05-8
- Staurosporine
Catalog No.:BCC3612
CAS No.:62996-74-1
- 6-Aminoquinoxaline
Catalog No.:BCC8767
CAS No.:6298-37-9
- XL335
Catalog No.:BCC4501
CAS No.:629664-81-9
- Neoprzewaquinone A
Catalog No.:BCN4169
CAS No.:630057-39-5
- MRS 2500 tetraammonium salt
Catalog No.:BCC5881
CAS No.:630103-23-0
- PD 168077 maleate
Catalog No.:BCC6919
CAS No.:630117-19-0
- AST 487
Catalog No.:BCC1373
CAS No.:630124-46-8
- Androstenone hydrazone
Catalog No.:BCC8830
CAS No.:63015-10-1
- Crenulatin
Catalog No.:BCN7791
CAS No.:63026-02-8
- Hexacosyl (E)-ferulate
Catalog No.:BCN4170
CAS No.:63034-29-7
- Senkyunolide
Catalog No.:BCN8154
CAS No.:63038-10-8
- H-Tle-OMe.HCl
Catalog No.:BCC2658
CAS No.:63038-27-7
- Estradiol-3-benzoate-17-butyrate
Catalog No.:BCC8963
CAS No.:63042-18-2
- Asunaprevir (BMS-650032)
Catalog No.:BCC1374
CAS No.:630420-16-5
- H-Val-OMe.HCl
Catalog No.:BCC3142
CAS No.:6306-52-1
Corynoxeine isolated from the hook of Uncaria rhynchophylla inhibits rat aortic vascular smooth muscle cell proliferation through the blocking of extracellular signal regulated kinase 1/2 phosphorylation.[Pubmed:18981576]
Biol Pharm Bull. 2008 Nov;31(11):2073-8.
The proliferation of vascular smooth muscle cells (VSMCs) induced by injury to the intima of arteries is an important etiologic factor in vascular proliferative disorders such as atherosclerosis and restenosis. Uncaria rhynchophylla is traditional Chinese herb that has been applied to the treatment of convulsive disorders, such as epilepsy, in China. In the present study, we examined whether Corynoxeine exerts inhibitory effects on platelet-derived growth factor (PDGF)-BB-induced rat aortic VSMC proliferation and the possible mechanism of such effects. Pre-treatment of VSMCs with Corynoxeine (5-50 microM) for 24 h resulted in significant decreases in cell number without any cytotoxicity; the inhibition percentages were 25.0+/-12.5, 63.0+/-27.5 and 88.0+/-12.5% at 5, 20 and 50 microM, respectively. Also, Corynoxeine significantly inhibited the 50 ng/ml PDGF-BB-induced DNA synthesis of VSMCs in a concentration-dependent manner without any cytotoxicity; the inhibitions were 32.8+/-11.0, 51.8+/-8.0 and 76.9+/-7.4% at concentrations of 5, 20 and 50 microM, respectively. Pre-incubation of VSMCs with Corynoxeine significantly inhibited PDGF-BB-induced extracellular signal-regulated kinase 1/2 (ERK1/2) activation, whereas Corynoxeine had no effects on mitogen-activated protein kinase (MAPK/ERK)-activating kinase 1 and 2 (MEK1/2), Akt, or phospholipase C (PLC)gamma1 activation or on PDGF receptor beta (PDGF-Rbeta) phosphorylation. These results suggest that Corynoxeine is a potent ERK1/2 inhibitor of key PDGF-BB-induced VSMC proliferation and may be useful in the prevention and treatment of vascular diseases and restenosis after angioplasty.
Isolation and identification of twelve metabolites of isocorynoxeine in rat urine and their neuroprotective activities in HT22 cell assay.[Pubmed:25519834]
Planta Med. 2015 Jan;81(1):46-55.
IsoCorynoxeine, one of the major alkaloids from Uncaria Hook, shows the effects of lowering blood pressure, vasodilatation, and protection against ischemia-induced neuronal damage. In this paper, the metabolism of isoCorynoxeine was investigated in rats. Twelve metabolites and the parent drug were isolated by using solvent extraction and repeated chromatographic methods, and determined by spectroscopic methods including UV, MS, NMR, and CD experiments. Seven new compounds were identified as 11-hydroxyisoCorynoxeine, 5-oxoisocorynoxeinic acid-22-O-beta-D-glucuronide, 10-hydroxyisoCorynoxeine, 17-O-demethyl-16,17-dihydro-5-oxoisoCorynoxeine, 5-oxoisocorynoxeinic acid, 21-hydroxy-5-oxoisoCorynoxeine, and oxireno[18, 19]-5-oxoisoCorynoxeine, together with six known compounds identified as isoCorynoxeine, 18,19-dehydrocorynoxinic acid, 18,19-dehydrocorynoxinic acid B, Corynoxeine, isoCorynoxeine-N-oxide, and Corynoxeine-N-oxide. Possible metabolic pathways of isoCorynoxeine are proposed. Furthermore, the activity assay for the parent drug and some of its metabolites showed that isoCorynoxeine exhibited a significant neuroprotective effect against glutamate-induced HT22 cell death at the maximum concentration. However, little or weak neuroprotective activities were observed for M-3, M-6, M-7, and M-10. Our present study is important to further understand their metabolic fate and disposition in humans.
